[go: up one dir, main page]

AU1075001A - Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions - Google Patents

Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Info

Publication number
AU1075001A
AU1075001A AU10750/01A AU1075001A AU1075001A AU 1075001 A AU1075001 A AU 1075001A AU 10750/01 A AU10750/01 A AU 10750/01A AU 1075001 A AU1075001 A AU 1075001A AU 1075001 A AU1075001 A AU 1075001A
Authority
AU
Australia
Prior art keywords
peptide
nucleic acid
immune responses
immunodeficiency virus
human immunodeficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10750/01A
Inventor
Denise Marie Baker
Esteban Celis
Robert Chesnut
Howard M. Grey
Ralph T. Kubo
Brian D Livingston
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of AU1075001A publication Critical patent/AU1075001A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU10750/01A 1999-10-05 2000-10-05 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions Abandoned AU1075001A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41286399A 1999-10-05 1999-10-05
US09412863 1999-10-05
PCT/US2000/027766 WO2001024810A1 (en) 1999-10-05 2000-10-05 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Publications (1)

Publication Number Publication Date
AU1075001A true AU1075001A (en) 2001-05-10

Family

ID=23634801

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10750/01A Abandoned AU1075001A (en) 1999-10-05 2000-10-05 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Country Status (5)

Country Link
EP (1) EP1225907A4 (en)
JP (1) JP4873810B2 (en)
AU (1) AU1075001A (en)
CA (1) CA2386499A1 (en)
WO (1) WO2001024810A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7790171B1 (en) * 2000-08-25 2010-09-07 Centre National De La Recherche Scientifique (C.N.R.S.) Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase
FR2824326B1 (en) * 2001-05-04 2004-03-19 Commissariat Energie Atomique MIXTURE OF PEPTIDES FROM PAPILLOMAVIRUS E6 AND / OR E7 PROTEINS AND THEIR APPLICATIONS
AU2002340880B2 (en) * 2001-09-07 2007-08-23 Polymun Scientific Immunbiologische Forschung Gmbh Peptides mimicking a cryptic epitope of GP41 HIV-1 and antibodies directed against them
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
JPWO2003029475A1 (en) * 2001-09-28 2005-01-20 株式会社ディナベック研究所 Mammalian cell-infecting viral vector encoding epitope-binding β2m and use thereof
EP1451214A2 (en) * 2001-11-26 2004-09-01 Hybrigenics Protein-protein interactions in human immunodeficiency virus
AU2003207835A1 (en) * 2002-02-04 2003-09-02 Auburn University Peptides for recognition and targeting of glial cell tumors
WO2004024173A2 (en) * 2002-09-13 2004-03-25 Creabilis Therapeutics S.P.A. A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
EP1431306A1 (en) * 2002-12-19 2004-06-23 Creabilis Therapeutics s.r.l. A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
EP1608675B1 (en) 2003-03-28 2011-08-17 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
WO2004106365A2 (en) * 2003-05-28 2004-12-09 Aventis Pasteur, Inc. Modulatory peptide motifs for inducing th1 or th2 immune response
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US7611712B2 (en) * 2003-10-23 2009-11-03 Nelson M. Karp Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide
ES2616337T3 (en) 2003-12-12 2017-06-12 Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors A human cytotoxic T lymphocyte epitope and its agonist epitope of the non-variable number of MUC-1 tandem repeat sequences
WO2005116055A1 (en) * 2004-05-24 2005-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptides, antibodies and compositions containing same useful for treating hiv virus infection
FR2874612A1 (en) * 2004-08-27 2006-03-03 Commissariat Energie Atomique HLA-DP4-RESTRICTED HIV CD4 + EP TOTES AND USES THEREOF
WO2006092046A1 (en) * 2005-03-01 2006-09-08 Variation Biotechnologies Inc. Hiv vaccine composition
US7501398B2 (en) * 2005-07-22 2009-03-10 Universita'degli Studi Di Milano Inhibitor of the folding of the HIV-1-protease as antiviral agent
BRPI0504117A (en) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epitopes, combination of epitopes, uses of epitopes or their combination, composition, uses of composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for identifying epitopes and methods for treatment or prevention.
CN104558126B (en) * 2006-03-10 2020-02-14 派特塞尔有限公司 Peptides, compositions and uses of HIV regulatory or accessory proteins
EP2021356B1 (en) * 2006-06-01 2010-10-27 Statens Serum Institut Hiv vaccine
WO2008068765A2 (en) * 2006-12-07 2008-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
CA2695399C (en) 2007-08-02 2017-10-17 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
JP2010536885A (en) * 2007-08-24 2010-12-02 ノバルティス アーゲー HIVENV protein with modifications in the V3 loop
WO2009043155A2 (en) * 2007-10-03 2009-04-09 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection
WO2010011343A2 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
WO2010041241A2 (en) * 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hiv-1 integrase derived peptides and compositions
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US8715685B2 (en) * 2009-07-14 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for HIV disease
ES2358829B1 (en) * 2009-10-23 2012-06-25 Lipotec, S.A. USEFUL PEPTIDES IN THE TREATMENT AND / OR CARE OF SKIN, MUCOSES AND / OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
WO2012062873A2 (en) * 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2452947A1 (en) * 2010-11-16 2012-05-16 Münch, Jan Viral infection enhancing peptide
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2694654B1 (en) 2011-04-07 2018-01-24 Her Majesty The Queen In Right of Canada as represented by The Minister of Health Protease cleavage site peptides as an hiv vaccine
IN2012DE00594A (en) * 2012-03-02 2015-08-21 Council Scient Ind Res
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
KR101476255B1 (en) * 2014-02-07 2014-12-26 대한민국 Recombinant peptide having T cell epitope derived from HIV-1 and vaccine composition comprising thereof
US20180346520A1 (en) * 2015-05-13 2018-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Methods and compositions for inducing an immune response using conserved element constructs
CN108779168A (en) * 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 HIV bonding agents
GB2549798A (en) 2016-04-29 2017-11-01 Univ Bradford Peptides and nanoparticle formulations thereof
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
US20220267373A1 (en) * 2018-10-31 2022-08-25 University Of Virginia Patent Foundation Self-assembling peptides and hydrogels
IT202000019708A1 (en) * 2020-08-07 2022-02-07 Ospedale Pediatrico Bambino Gesù Angiotensin-converting enzyme 2 (ACE2) receptor-binding peptides and their medical uses
CA3192758A1 (en) * 2020-09-04 2022-03-10 Dompe' Farmaceutici Spa Peptides endowed with angiogenic activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
EP0346022B1 (en) * 1988-06-10 1996-02-14 United Biomedical, Inc. Peptide fragments of HIV
FR2677654B1 (en) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc COMPOUNDS WITH AN IMMUNOGENIC ANTI-CYTOKIN EFFECT, AN ANTIYTOSTATIC IMMUNOGENIC EFFECT OR AN ANTI-HIV INFECTION VACCINE EFFECT.
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
JP3908271B2 (en) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド HLA-A2.1 binding peptides and their use
AU698962B2 (en) * 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
KR100235849B1 (en) * 1993-10-19 1999-12-15 에가시라 구니오 Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
JP4210735B2 (en) * 1996-03-21 2009-01-21 ファーメクサ インコーポレイテッド HLA-A2.1 binding peptide and use thereof
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
WO1999049893A1 (en) * 1998-03-31 1999-10-07 Trustees Of Boston University Methods for designing molecular conjugates and compositions thereof

Also Published As

Publication number Publication date
CA2386499A1 (en) 2001-04-12
WO2001024810A1 (en) 2001-04-12
JP4873810B2 (en) 2012-02-08
EP1225907A1 (en) 2002-07-31
EP1225907A4 (en) 2005-06-22
JP2003510099A (en) 2003-03-18

Similar Documents

Publication Publication Date Title
AU1075001A (en) Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
AU2087401A (en) Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
AU6226100A (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
AU7828100A (en) Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions
AU2605501A (en) Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions
AU3730600A (en) Compositions preparations and uses of human papillomavirus l1 protein
AU3727695A (en) Compositions and methods for the abrogation of cellular proliferation utilizing the human immunodeficiency virus vpr protein
AU2086501A (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide andnucleic acid compositions
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
AU2002219988A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2085001A (en) Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
IL113484A0 (en) Viral proteins pharmaceutical compositions containing them their preparation and use
AU1608201A (en) Human zven proteins
AU2088701A (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
AU5405500A (en) Novel amino sulfonamides and amido sulfonamides as antiviral agents
ZA943438B (en) Peptides of human influenza virus for ue in human t cell response inducing compositions
AU4338100A (en) Secreted human proteins
IL131266A0 (en) Peptides and pharmaceutical compositions comprising same
IL149506A0 (en) Human heparanase-related polypeptide and nucleic acid
AU7563798A (en) Methods and compositions for administering dna to mucosal surfaces
AU4942197A (en) Dna-constructs comprising intergenic ribosomal dna and methods to produce proteins using these dna-constructs
AU2960000A (en) Detection of human immunodeficiency virus
AU2001297804A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002237733A1 (en) Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
HK1057704A (en) Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase